Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00165789 · ClinicalTrials.gov registry record · Phase 2
A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations
A Phase 2 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT00165789 is a Phase 2 study that has completed, run by Eisai. The registered enrollment target is 75 participants.
The verdict
NCT00165789, a Phase 2 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, two treatment, two group, parallel group study. Subjects will be randomized to one of two treatment groups (E2007 or Placebo) in a 3 to 1 ratio and receive treatment for a total of ten weeks (Days 1 to 70).
Interventions
- DRUG E2007
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2005-09 |
| Est. Completion | 2006-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00165789
The ClinicalTrials.gov registry entry for NCT00165789 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which E2007 is the first listed.
NCT00165789 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00165789 about?
NCT00165789 is a clinical study titled "A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations". This is a randomized, double-blind, two treatment, two group, parallel group study. Subjects will be randomized to one of two treatment groups (E2007 or Placebo) in a 3 to 1 ratio and receive treatment for a total of ten weeks (Days 1 to 70).
What is the current status of trial NCT00165789?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2005-09. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00165789?
The interventions under investigation include: E2007 (DRUG).
Who is sponsoring clinical trial NCT00165789?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.